BioSpace News Archive

Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional patients in the ABACUS study of KIO-301

Pacylex Pharmaceuticals, a clinical stage pharmaceutical company focused on the development of therapies for hematologic and solid cancers,

The publication named “Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting” was led by Dr. Talia Golan, Head of the Pancreatic Cancer Center at Sheba medical center, which is ranked one of the top 10 hospitals in the world by Newsweek, and by Chani Stossel, Ph.D., at the Oncology Institute.

oday, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Rosalind Franklin University’s 2nd Annual Biomedical Innovation Day, “Breaking New Ground in Cancer, Immunology and Infection,” will be held virtually and in-person on Oct. 18

PHAXIAM Therapeutics and Vetophage announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins in the fight against antimicrobial resistance.

SeaStar Medical Holding Corporation announces receipt of a correspondence from the U.S. FDA’s CBER indicating that the Agency considers the SCD-PED to be approvable under a Humanitarian Device Exemption for use in children weighing 10 kilograms or more with acute kidney injury and sepsis or a septic condition requiring continuous kidney replacement therapy in the hospital intensive care unit.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman, effective October 3, 2023.

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the Company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD).